[18F]92

The drug [18F]92 is a novel positron emission tomography (PET) tracer developed for imaging β-amyloid (Aβ) plaques in the brain. This radiopharmaceutical has shown high binding affinity to aggregated β-amyloid and demonstrates excellent pharmacokinetic properties in the human brain. It can be synthesized automatically using the AllinOne radiosynthesis module, yielding high radiochemical purity and yield. The tracer rapidly crosses the blood-brain barrier within 10 minutes after injection. [18F]92 is primarily being investigated for the diagnosis of Alzheimer's disease (AD). Dynamic PET scans have shown excellent pharmacokinetic properties, with standardized uptake value ratio (SUVR) values stabilizing around 60-70 minutes after injection. It effectively differentiates between Aβ-positive and Aβ-negative individuals, showing significantly higher SUVRs in the cerebral cortex of Aβ-positive participants. Additionally, correlations with plasma biomarkers of AD have been observed. It shows promise as a reliable radiotracer for estimating Aβ pathology accumulation, potentially assisting in AD diagnosis and guiding clinical trials of therapeutic drugs.

Other names

[18F]-4-((*E*)-(((*E*)-4-(2-(2-(2-Fluoroethoxy)ethoxy)ethoxy)benzylidene)-hydrazono)methyl)-*N*-methylaniline